Devita, Hellman, and Rosenberg's Cancer

LWBK1006-44 LWW-Govindan-Review November 24, 2011 11:30

552 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 44.3. A 50-year-old man with metastatic non-small cell lung cancer is receiving

carboplatin, paclitaxel, and bevacizumab therapy. He is also receiving

darbepoetin to support chemotherapy-induced anemia. He presents with

right arm swelling and is found to have extensive clot extending from his

central venous catheter, into his right brachiocephalic, internal jugular,

and axillary veins. Which of the following factors likely contributed to

deep venous thrombosis in this gentleman?

A. Presence of a central venous catheter

B. Bevacizumab

C. Darbepoetin

D. All of the above

Question 44.4. Regarding the use of prophylactic anticoagulation for central venous

catheters, which of the following statements is TRUE?

A. Fixed-dose warfarin is more effective than low-molecular-weight hep-

arin.

B. Symptomatic catheter-related thrombosis rates of 15% were reported

without the use of prophylaxis.

C. The American College of Chest Physicians (ACCP) 2008 guide-

lines recommend against the use of routine prophylaxis using low-

molecular-weight heparin and fixed-dose warfarin.

D. The use of fixed-dose warfarin (1 mg daily) is not associated with

increased bleeding risk.

Question 44.5. Chemotherapy-induced nausea and vomiting (CINV) include which of

the following types?

A. Acute CINV

B. Delayed CINV

C. Anticipatory CINV

D. All of the above

Question 44.6. Patient-related factors important in increased risk of CINV include all of

the following, EXCEPT:

A. Female gender

B. Younger age

C. History of chronic alcohol consumption

D. History of motion sickness

Question 44.7. Recommended antiemetic therapy for the prevention of acute emesis with

high emetic risk chemotherapy include all of the following, EXCEPT:

A. 5-HT 3 receptor antagonist

B. Phenothiazine

C. Aprepitant

D. Dexamethasone